Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Tanespimycin (formerly NSC-330507; CP-127374; 17-AAG, BAY-579352, KOS-953, 17-AAG, CP-127374), a benzoquinone analog and a derivative of the antibiotic geldanamycin, is an orally bioavailable and small-molecule inhibitor of heat shock protein 90/HSP90 with potential antitumor activity. It inhibits HSP90 with an IC50 of 5 nM in a cell-free assay. Tanespimycin is being studied for the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors.
ln Vitro |
Tanespimycin degrades HER2, Akt, and the G1 growth halt of prostate cancer cells that is dependent on retinoblastoma as well as mutant and wild-type AR. With IC50 values ranging from 25 to 45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM), tantespimycin suppresses prostate cancer cell lines [1]. Tanespimycin (0.1–1 μM) causes breast cancer cells that overexpress ErbB2 to almost completely lose ErbB2[2]. Tanespimycin downregulates Bcl-2, Survivin, and Cyclin B1, and upregulates cleaved PARP. These effects prevent the development of CCA cells and cause G2/M cell cycle arrest and apoptosis[3].
|
||
---|---|---|---|
ln Vivo |
In prostate cancer xenografts, tantespimycin (25–200 mg/kg, ip) reduces AR, HER2, and Akt expression in a dose-dependent manner. At doses high enough to cause the degradation of HER2, Akt, and AR, tantespimycin dose-dependently suppresses the growth of androgen-dependent and -independent prostate cancer xenografts without causing toxicity [1]. Through tail vein injection, tanespimycin (60 mg/kg) and Rapamycin (30 mg/kg) impacted tumor cure in MDA-MB-231 tumor-bearing rats by inhibiting the growth of A549 and MDA-MB-231 tumors [4].
|
||
Animal Protocol |
|
||
References |
[1]. Solit DB, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.Clin Cancer Res, 2002, 8(5), 986-993.
[2]. Raja, Srikumar M., et al. 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biology & Therapy (2008), 7(10), 163 [3]. Zhang J, et al. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.Clin Exp Med. 2012 Sep 7. [4]. Newman B, et al. HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells.Cancer Res. 2012 Sep 1;72(17):4551-61. Epub 2012 Jun 29. [5]. Kamal A, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003 Sep 25;425(6956):407-10. [6]. Enomoto A, et al. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. Eur J Cancer. 2013 Nov;49(16):3547-58 |
Molecular Formula |
C31H43N3O8
|
|
---|---|---|
Molecular Weight |
585.69
|
|
CAS # |
75747-14-7
|
|
Related CAS # |
|
|
SMILES |
NC(O[C@@H](/C(C)=C/[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC1=C2NCC=C)[C@@H](OC)/C=C/C=C(C)/C(NC(C1=O)=CC2=O)=O)=O
|
|
InChi Key |
AYUNIORJHRXIBJ-HTLBVUBBSA-N
|
|
InChi Code |
InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9+,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
|
|
Chemical Name |
(4E,6E,8S,9S,10E,12S,13R,14S,16R)-19-(allylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate.
|
|
Synonyms |
NSC330507; CP127374; 17-AAG, BAY 579352, KOS-953, 17 AAG, CP-127374, NSC-330507, NSC 330507; CP 127374; 17AAG, BAY 57-9352, BAY579352, KOS 953, KOS953, Tanespimycin
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (8.54 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (8.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 5 mg/mL (8.54 mM) in 15% Cremophor EL + 85% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Solubility in Formulation 4: ≥ 1.62 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.2 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.. Solubility in Formulation 5: 5%DMSO+corn oil: 10 mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7074 mL | 8.5369 mL | 17.0739 mL | |
5 mM | 0.3415 mL | 1.7074 mL | 3.4148 mL | |
10 mM | 0.1707 mL | 0.8537 mL | 1.7074 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00118248 | Completed Has Results | Drug: tanespimycin | Recurrent Thyroid Cancer Stage IV Follicular Thyroid Cancer |
National Cancer Institute (NCI) | December 2004 | Phase 2 |
NCT00564928 | Completed | Drug: IPI-504 | Prostate Cancer Prostatic Neoplasms |
Infinity Pharmaceuticals, Inc. | November 2007 | Phase 2 |
NCT00098423 | Completed | Drug: tanespimycin Drug: cytarabine |
Accelerated Phase Chronic Myelogenous Leukemia |
National Cancer Institute (NCI) | November 2004 | Phase 1 |
NCT00093821 | Completed | Drug: tanespimycin | Childhood Chronic Myelogenous Leukemia |
National Cancer Institute (NCI) | September 2004 | Phase 1 |